ICTHIC magazine

25/03/2026

ICTHIC 2026 is approaching...

11/01/2026

📢New abstract deadline!

📌Take advantage of the early registration (deadline: January, 31st, 2026): lnkd.in/dJMRWEkW

📩 Submit your abstract here: icthic.abstracts.it (deadline: January, 18th, 2026)

07/01/2026

⌛️Only 3 days left to submit your abstract!

📌Take advantage of the early registration (deadline: January, 31st, 2026): lnkd.in/dJMRWEkW

📩 Submit your abstract here: icthic.abstracts.it (deadline: January, 10th, 2026)

04/01/2026

⌛️Only 6 days left to submit your abstract!

📌Take advantage of the early registration (deadline: January, 31st, 2026): lnkd.in/dJMRWEkW

📩 Submit your abstract here: icthic.abstracts.it (deadline: January, 10th, 2026)

24/05/2023

Bleeding risk, cancer, and atrial fibrillation, what do we know?

A connection exists between cancer and atrial fibrillation (AF) as cancer is statistically associated with AF within the first 3 months after a cancer diagnosis.

A diagnosis of AF carries a risk of a cancer diagnosis as well.

Patients with cancer also have an increased risk of developing venous thromboembolism (VTE) and major bleeding, especially when they begin anticoagulation therapy.

While specific scores are available to evaluate VTE risk in cancer patients, the standardized risk models available for AF (CHA2DS2-VASC and HAS-BLED score) do not consider the presence of malignancy.

Keep reading the article here.

👇👇👇

Cancer and atrial fibrillation A connection exists between cancer and atrial fibrillation (AF) as cancer is statistically associated with AF within the first 3 months after cancer diagnosis [1]. A review and metanalysis highlighted that people with newly diagnosed cancer had a significantly increase...

10/03/2023

A new ICTHIC webinar is coming soon!

Challenges in the management of fragile CAT patients (older patient population & palliative care)
15 MAY 2023 – 18:00-19:00 CET

Speakers: Jay Easaw, Simon Noble, Thomas R.J. McFarlane
Annie Young will chair this event.

Check out the agenda 👉👉 https://rb.gy/7ffhu1

The webinar is free to attend, and an application has been made to the UEMS EACCMER® for CME accreditation.

28/11/2022

Check out the next ICTHIC Magazine webinar:

Long-term treatment & DDI implications in the management of CAT
29 November 2022 – 18:00-19:00 CET

Speakers: Luis Jara Palomares, Hans-Peter Lipp, Tzu-Fei Wang
Marc Carrier will chair this event.

👉👉 https://rb.gy/watrjm

The webinar is free to attend, and it has been granted 1 European CME credit (ECMEC®) by the European Accreditation Council for Continuing Medical Education (EACCME®).

01/04/2022

The first ICTHIC podcast is live. Check it out 👇👇👇

Cliona Kirwan, professor in surgical clinical trials at the University of Manchester, talks about thrombosis and coagulation management in breast cancer.

Breast cancer is the most commonly diagnosed cancer in women accounting for a quarter of cancer cases worldwide. This equates to about 2.3 million women being diagnosed in 2020, with incidence rates increasing worldwide. In addition to this, breast cancer survival rates in both early and metastatic....

04/03/2022

What is the use of direct oral anticoagulants in pediatric cancer patients?

Most children with cancer-associated thrombosis are still treated with low-molecular-weight heparin.

Unlike adults, direct oral anticoagulants (DOACs) have not been approved in the pediatric population until recently, when rivaroxaban was approved for pediatric use by the EMA and the FDA.

The phase III Einstein Jr multicenter randomized controlled study (NCT02234843) showed that rivaroxaban is safe and effective in children with VTE.

The DIVERSITY study (NCT01895777), compared the efficacy and safety of dabigatran etexilate to the standard of care in pediatric patients with VTE. The results indicate that dabigatran was non-inferior to the standard of care in terms of efficacy and might be a suitable alternative to care standards. However, in this study, there was not a represented population for cancer patients.

Therefore, the use of DOACs in children will certainly increase in the future, but it will take time since many drugs are not registered yet for pediatric cancer patients.

Read and watch the Prof. Kenet's full interview https://rb.gy/dvlkdf